We determined risk factors associated with persistent carriage of methicill
in-resistant Staphylococcus aureus (MRSA) among 102 patients enrolled in a
double-blind, placebo-controlled trial of nasally administered mupirocin oi
ntment. MRSA decolonization was unsuccessful in 77 (79%) of 98 patients who
met the criteria for evaluation. By univariate analysis, 4 variables were
found to be associated with persistent MRSA colonization (P<.1 for all 4):
absence of mupirocin treatment, previous fluoroquinolone therapy, <greater
than or equal to>2 MRSA-positive body sites, and low-level mupirocin resist
ance. After multivariable Cox proportional hazards modeling, the presence o
f greater than or equal to2 positive body sites (adjusted hazard ratio [AHR
], 1.7; 95% confidence interval [CI], 1.0-2.9) and previous receipt of a fl
uoroquinolone (AHR, 1.8; 95% CI, 1.0-3.3) were independently associated wit
h MRSA persistence, whereas nasal mupirocin tended to confer protection (AH
R, 0.6; 95% CI, 0.4-1.0). Low-level mupirocin resistance was observed in 9
genotypically different MRSA strains and was not independently associated w
ith chronic MRSA carriage (AHR, 1.5; 95% CI, 0.9-2.5). Our findings suggest
that multisite MRSA carriage and previous receipt of a fluoroquinolone are
independent risk factors for persistent MRSA colonization.